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A B S T R A C T
Tobacco smoking is a global pandemic that poses substantial health burdens and costs. With nearly six million
deaths annually, smoking is the single most important cause of avoidable premature mortality in the world,
mainly from lung cancer, coronary heart disease, chronic obstructive pulmonary disease and stroke. Smoking is a
very difficult addiction to break, even for those with a strong desire to quit. Electronic cigarettes are an attractive
long-term alternative source of nicotine to conventional cigarettes because of their many similarities with
smoking. Electronic cigarette users report buying them to reduce cigarette consumption, to relieve tobacco
withdrawal symptoms, to quit, and to continue having a ‘smoking’ experience, but with reduced health risks.
Actually, there aren't antismoking treatments for people who smoke only electronic cigarette (single users) or
electronic cigarette and classic cigarette (dual users). There isn't any specific information on the efficacy and
safety of new pharmacological support for electronic cigarette users. We propose that smoking cessation with
varenicline plus counselling delivered to electronic cigarette users could be associated with similar smoking
abstinence rates compared to the results obtained in the general population. Herein, we describe the metho-
dology of a double-blind, placebo-controlled, randomized clinical trial, of 24 weeks duration, that examines the
efficacy of varenicline (1mg BID - for 12 weeks) plus counselling compared to matched placebo (1mg BID - for
12 weeks) plus counselling.
1. Introduction
Tobacco smoking is a global pandemic, affecting an estimated 1.2
billion people, that poses substantial health burdens and costs [1]. With
nearly six million deaths annually, smoking is the single most important
cause of avoidable premature mortality in the world, mainly from lung
cancer, coronary heart disease, chronic obstructive pulmonary disease
and stroke [1]. As also underscored by the World Health Organization
Framework Convention on Tobacco Control, the key to reducing the
health burden of tobacco in the medium term is to encourage cessation
among smokers [2]. Unfortunately, smoking is a very difficult addiction
to break, even for those with a strong desire to quit. It has been shown
that approximately 80% of smokers who attempt to quit on their own
relapse within the first month of abstinence, and only about 5% achieve
long term abstinence [3]. Electronic cigarettes are an attractive long-
term alternative source of nicotine to conventional cigarettes because of
their many similarities with smoking. E-cigarettes users report buying
them to reduce cigarette consumption, to relieve tobacco withdrawal
symptoms, to quit, and to continue having a ‘smoking’ experience, but
with reduced health risks [4]. There aren't antismoking treatments for
people who smoke only electronic cigarette (single users) or electronic
cigarette and classic cigarette (dual users). Surprisingly, there aren't
data available in the literature on smoking cessation intervention for
this specific disease group and also, no specific information on the ef-
ficacy and safety of new pharmacological support for electronic cigar-
ettes users.
Varenicline is a partial agonist of the α4β2 nicotinic acetylcholine
receptor that causes partial stimulation while it competitively inhibits
nicotine binding. Recently, randomized, controlled clinical trials have
shown that varenicline at a dose of 1mg twice a day is superior to
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placebo for smoking cessation [5,6]. Varenicline appears to be also
more effective than sustained-release bupropion [7]. Data from these
trials indicate that the most common adverse event attributed to var-
enicline at a dose of 1mg twice daily is nausea [5–7]. However, the
efficacy and safety of varenicline has never been tested in electronic
cigarette users interested in stopping e-cigarettes and only a recent
study investigated if ‘dual users’ who smoke and use e-cigarettes are
interested in stopping smoking by using varenicline [8]. However,
question arises whether people who smoke only electronic cigarette
(single users) or electronic cigarette and classic cigarette (dual users)
could benefit from using an integrated smoking cessation programme
that combine varenicline plus smoking cessation counselling. Dual use
is an emerging phenomenon and while there is no consensus on its
definition, in most evidence-based literature it is commonly referred to
as those who use both e-cigarettes and classic cigarettes whereas those
who smoke only e-cigarettes are referred to as single [9]. While tradi-
tional cigarette combustion generates toxic substances correlated with
cancers, respiratory and cardiovascular disorders, long term e-cigar-
ettes usage could determine adverse events such as mouth and throat
irritation and or a psychological need in the vaper to no longer use the
e-cigarette to be free from any form of possible nicotinic addiction.
Therefore, we designed a randomized controlled study to test the
effectiveness of a smoking cessation programme with varenicline in
electronic cigarette users. We hypothesized that smoking cessation with
varenicline could be associated with similar smoking abstinence rates
compared to the results obtained in the general population. Given that a
better understanding of predictors of smoking cessation can be useful in
identifying potential quitters and likely relapsers [10] and that little is
known about these predictors in e-cigarettes users, the role of different
predictors of abstinence at the end of the study will also be examined.
2. Design and methods
2.1. Overview and design
The study is a double-blind, placebo-controlled, randomized clinical
trial. It will be designed as a parallel two-group RCT of 24 weeks
duration with participants being randomized to either coun-
seling + varenecline (1 mg BID) for 12 weeks or to coun-
seling + matched placebo. The duration of active treatment will be 12
weeks.
A final visit is scheduled for week 24; abstinence from smoking and
vaping will be recorded and evaluated objectively by the levels of saliva
cotinin. Vital signs and weight will be measured. This final visit will be
conducted by a researcher who is not aware of the group allocation of
the study participants.
2.2. Outcome measures
The primary outcome for the study is a comparison of varenicline to
placebo for the Continuous Abstinence Rate (CQR) for Weeks 9 through
24. This measure will be obtained through reports of cigarette, e-ci-
garette and other nicotine use since the last study visit confirmed by a
measurement of an end-expiratory exhaled carbon monoxide con-
centration that is≤ 10 ppm and by saliva cotinine levels. Cotinine
saliva levels will be measured to further objectively verify smoking
status. A cut off of< 7 ng/ml of cotinine will distinguish smokers from
nonsmokers.
Additional study outcomes measures of interest will be: 1. Safety
end-points for varenecline; 2. Predictors of abstinence (e.g. gender, age
at smoking initiation, previous quit attempts, FTCD, motivation, de-
pression, anxiety, social/familial environment, etc.) at the end of the
study; 3. Percentage of participants' retention in the study.
Safety end-points: 1. Adverse events: Adverse events (AEs) observed
or reported will be recorded on the case report form. Assessments as to
seriousness, severity, and the relationship to treatment and other causes
will be made. Serious adverse events (SAEs) will also be captured in the
centralized database. AEs and SAEs will be reported to the appropriate
regulatory agency(ies); 2. Physical Examination: Physical examination
will be performed at the screening visit and at Week 12; 3. Blood
pressure, pulse rate, and temperature: Blood pressure and pulse rate
will be measured at all clinic visits. Temperature will be measured at
the baseline visit; 4. Electrocardiogram: An electrocardiogram will be
obtained at screening; 5. Body weight: Body weight will be measured at
all visits. It will be measured in indoor clothing without shoes.
2.3. Overview of intervention
Before the baseline visit, a face to face screening (V0) for pre-elig-
ibility checks will be conducted.
At screening visit, participants will be seen in a screening visit,
during which informed consent will be obtained prior to any study
procedures. Physical examination, blood pressure, pulse rate cardiolo-
gical visit and electrocardiogram will be done. A serum pregnancy test
will be completed for all females at the screening.
At baseline visit a standardized questionnaire will be used to collect
relevant information on: 1) sociodemographic factors: age, sex, level of
education, and marital status; 2) history of tobacco use: number of daily
smoked cigarettes, years of smoking, pack/years, smoking status of
other members of the household, previous quit attempts; 3) motivation
score by visual analogic score, nicotine dependence by FTCD and e-
cigarettes dependence by Penn State Electronic Cigarette Dependence
Index; 4) depression and anxiety will be assessed by Beck Depression
Inventory (BDI) and by Beck Anxiety Inventory (BAI) respectively. BMI
(obtained from the patients’ clinical diary) will also be recorded.
Concentration of monoxide carbon will be also measured.
Participants will be then instructed on how to prepare to stop
smoking and to set a quit date. A serum pregnancy test will be com-
pleted for all females.
Each participant will be randomly assigned to either varenicline
1 mg BID + counselling or matched placebo + counselling using a
form of adaptive randomization designed to minimize imbalances in the
distribution of prognostic factors (gender, depression, motivation,
previous quit attempts, and level of nicotine dependence) between
study groups. The randomized assignment will be blinded.
All participants will be offered smoking cessation counselling over
several brief (10–20min) office appointments.
Visits from week 1 to week 12. The first follow up appointment will
be timed within 48 h from the set quit date. On each occasion, self-
reported smoking status will be checked and verified by saliva cotinine,
occurrence of tobacco withdrawal symptoms (such as anxiety, rest-
lessness, poor concentration, irritability, insomnia, depression, craving,
stypsis and increased appetite) evaluated, adherence to medication
reviewed, and any difficulty related to their smoking cessation efforts
discussed in detail. The Week 1 visit must be scheduled to occur 8 days
after the baseline visit, so that subjects have a full 7 days of treatment
prior to the TQD (target quit date). Subjects will return for visits to the
clinic after the baseline visit over the following 12weeks at Weeks 1, 2,
3, 4, 8 and 12. Subsequent to Week 1, visits will occur within 3 days of
each scheduled visit date. The subjects will attempt to quit on the target
quit date at the Week 1 visit (8 days after the baseline visit). All con-
comitant medications and any adverse events will be recorded. Vital
signs and weight will be measured. Exclusively at week 12 a serum
pregnancy test will be completed for all females.
Varenecline should be discontinued immediately if patients show
agitation, depressed mood, or changes in behaviour that create con-
cerns in the doctor, the patient, family or those who take care of the
patient, or if the patient develops suicidal ideation or suicidal beha-
viour.
Non-treatment Follow-up (Weeks 13 through 24). Participants will
attend a final visit (week 24); abstinence from smoking and vaping will
be recorded and objectively assessed by saliva cotinine levels. Vital
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signs and weight will be measured. This final visit will be conducted by
a physician who is unaware of the group allocation of the study parti-
cipants.
2.4. Study schedule
Screening visit (V1): Screening visit for eligibility criteria. Will be
delivered informed consent will be obtained prior to any study proce-
dures. Physical examination, blood pressure, pulse rate cardiological
visit and electrocardiogram will be done. A serum pregnancy test will
be completed for all females at the screening (Table 1).
Baseline (Visit 2): a standardized questionnaire will be used to
collect relevant information on: 1) sociodemographic factors: age, sex,
level of education, and marital status; 2) history of tobacco use: number
of daily smoked cigarettes, years of smoking, pack/years, smoking
status of other members of the household, previous quit attempts; 3)
motivation score by visual analog score, nicotine dependence by FTND
and e-cigarettes dependence by Penn State Electronic Cigarette
Dependence Index; 4) depression and anxiety assessed by Beck
Depression Inventory (BDI) and by Beck Anxiety Inventory (BAI) re-
spectively. BMI (obtained from the patients’ clinical diary) will also be
recorded. Concentration of monoxide carbon will be also measured.
Participants will be then instructed on how to prepare to stop smoking
and to set a quit date. A serum pregnancy test will be completed for all
females.
Each participant will be randomly assigned to either varenicline
1 mg BID + counselling or matched placebo + counselling using a
form of adaptive randomization designed to minimize imbalances in the
distribution of prognostic factors (gender, depression, motivation,
previous quit attempts, and level of nicotine dependence) between
study groups. The randomized assignment will be blinded.
All participants will be offered smoking cessation counselling over
several brief (10–20min) office appointments (Table 1).
Visit 3: self-reported smoking status will be checked and verified by
saliva cotinine, occurrence of tobacco withdrawal symptoms (such as
anxiety, restlessness, poor concentration, irritability, insomnia, de-
pression, craving, stypsis and increased appetite) evaluated, adherence
to medication reviewed, and any difficulty related to their smoking
cessation efforts discussed in detail (Table 1).
Visit 4: during this visit these parameters will be evaluated: ECO
(exhaled Carbon Monoxide), Counselling, Dispense study drug,
Smoking status, Saliva cotinine (in case of self-declaration of quitting),
Minnesota Nicotine Withdrawal Scale, Adherence to medication,
Adverse events, Concomitant medication, Vital signs (temperature only
BL), and Weight (Table 1).
Visit 5: during this visit these parameters will be evaluated: ECO
(exhaled Carbon Monoxide), Counseling, Dispense study drug, Smoking
status, Saliva cotinine (in case of self-declaration of quitting),
Minnesota Nicotine Withdrawal Scale, Adhrence to medication,
Adverse events, Concomitant medication, Vital signs (temperature only
BL), and Weight (Table 1).
Visit 6: during this visit these parameters will be evaluated: ECO
(Exhaled Carbon Monoxide), Counseling, Dispense study drug, Smoking
status, Saliva cotinine (in case of self-declaration of quitting),
Minnesota Nicotine Withdrawal Scale, Adherence to medication,
Adverse events, Concomitant medication, Vital signs (temperature only
BL), and Weight (Table 1).
TC 1: it consists of a telephone contact in which the participant will
be asked to report his smoking status and offered counselling.
Visit 7: during this visit these parameters will be evaluated: ECO
(exhaled Carbon Monoxide), Counseling, Dispense study drug, Smoking
status, Saliva cotinine (in case of self-declaration of quitting),
Minnesota Nicotine Withdrawal Scale, Adherence to medication,
Adverse events, Concomitant medication, Vital signs (temperature only
BL), and Weight (Table 1).
TC 2: it consists of a telephone contact in which the participant will
be asked to report his smoking status and offered counselling.
Visit 8: at week 12 a serum pregnancy test will be completed for all
Table 1
Study schedule/flowchart.
Procedure Screen BL Wk 1 Wk 2 Wk 3 Wk 4 Wk 5 Wk 6 Wk 7 Wk 8 Wk 12
VISIT 1 VISIT 2 VISIT 3 VISIT 4 TC VISIT 5 TC VISIT 6 TC VISIT 7 VISIT 8




Vital signs (HR, BP, WEIGHT) X X X X X X X X X
Sociodemografic factors X
Adverse events X X X X X X X X X X
Antidiabetic drug use X X X X X X X X X X
FTND X
Motivation by VAS X
BDI & BAI X
GN-SBQ X
Nicotine Use Inventory X X X X X X X X X X
Blood chemistry, CBC X X X
Urinalysis X X X
DM lab tests X
Pregnancy test X
eCO X X X X X X X X
Counseling X X X X X X X X X X
Dispense study drug X X X X X X X
Dosing record X X X X X X X
BL= baseline; TC= telephone contact; HR=heart rate; BP=blood pressure.
FTND= Fagerstrom Test for Nicotine Dependence; VAS= visual analog score.
BDI=Beck Depression Inventory; BAI=Beck Anxiety Inventory.
eCO= exhaled carbon monoxide.
Wk1 must be scheduled 8 days after the baseline visit.
Dispense study drug – a week supply of drug/placebo is dispensed at each visit with the exception of Wk 4, Wk 6, Wk 8 and Wk 10 when a whole 2 weeks supply is
given.
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females. Moreover, the parameters of ECO (exhaled Carbon Monoxide),
Counseling, Smoking status, Saliva cotinine (in case of self-declaration
of quitting), Minnesota Nicotine Withdrawal Scale, Adherence to
medication, Adverse events, Concomitant medication, Vital signs
(temperature only BL), and Weight (Table 1).
TC 3: it consists of a telephone contact in which the participant will
be asked to report his/her smoking status and offered counselling.
Visit 9: Participants will attend a final visit 9 (week 24); abstinence
from smoking and vaping will be recorded and objectively assessed by
saliva cotinine levels. Vital signs and weight will be measured. This
final visit will be conducted by a physician who is unaware of the group
allocation of the study participants (Table 2).
2.5. Active intervention
Varenicline was discovered through the synthesis of a series of
compounds inspired by the natural product, cytisine, which was pre-
viously known to have partial agonist activity at the α4β2 nAChR [5].
Varenicline was found to be a selective partial agonist at the α4β2
nAChR, displaying ~30–60% of the in vivo efficacy of nicotine, and it
also effectively blocked the in vivo response to nicotine [5]. Varenicline
has been available as a pharmacotherapy for smoking cessation since
2006. Smoking cessation by the help of varenicline is accepted as a
reliable monotherapy to provide high smoking abstinence rates [6].
Varenicline is selective partial agonist of the alpha4–beta2 nicotinic
acetylcholine receptor [7]. Among patients not able to quit smoking,
use of varenicline for 24 weeks significantly increased smoking cessa-
tion [8].
Administration: Treatment will begin on the day after the baseline
visit. The subjects will take a total of one 0.5 mg tablets per day for the
first 3 days of the dosing period. In the morning, the first blinded
varenicline tablet on the dosing cards will be taken. The dosing will
then increase for the next 4 days to two tablets per day, 1 in the
morning and 1 in the evening. The dosing will then increase to four
tablets per day, 2 in the morning and 2 in the evening for the remainder
of the study.
2.6. Participants
140 Caucasian e-cigarettes users, vaping nicotine-containing liquids
daily for> 3 months (single users); and 140 Caucasian ecigs users,
vaping nicotine-containing liquids daily for > 3 months; who also
smoke at least one conventional cig/day (i.e. dual users) and willing to
quit, will be invited to participate in the study.
Inclusion Criteria: Male or female ages of 18 and 75 years, inclusive,
who are motivated to stop smoking. Females of nonchildbearing po-
tential (surgically sterilized or at least 2 years postmenopausal) who are
not nursing may be included. Females of childbearing potential may be
included provided that they are not pregnant, not nursing, and are
practicing effective contraception and meet all of the following criteria:
1. Are instructed and agree to avoid pregnancy through 30 days after
the last dose of study medication,
2.7. Have a negative serum pregnancy test (β-hCG) at screening and
baseline, and
3. Agree to use one of the birth control methods listed below:• an oral contraceptive agent, an intrauterine device (IUD), an im-
plantable contraceptive, or an injectable contraceptive for at least
one month prior to entering the study and will continue its use
through at least 30 days after the last dose of study medication,• a barrier method of contraception, e.g., condom and/or dia-
phragm with spermicide while participating in the study through
at least 30 days after the last dose of study medication.
Exclusion Criteria: Patients with a history of alcoholism; History of
epilepsy; Comorbid psychiatric disorders (Schizophrenia, Major
Depression, Bipolar Disorder); History of psychiatric disorders; History
of suicide attempts within the past three months and/or current suicidal
ideation/plan and subjects at risk for the development of depressive
symptom; Pregnant and breastfeeding women will be excluded: Patients
with severe renal impairment and symptomatic vascular disease (in-
cluding a history of ischaemic heart disease, stroke) will be also ex-
cluded from the study.
2.8. Statistical methods
Though inferences will be model based, sample sizes are approxi-
mated based on the comparison of varenicline 1mg BID vs placebo,
using a two-group continuity-corrected Chi-Squared test with a 0.050
two-sided significance level. The sample size calculation for this RCT,
based on the expected cessation rates from our previous smoking ces-
sation study, indicates that a totally of 138 subjects will be required to
have 80% power with two-sided 0.05 significance level test to detect a
difference of at least 20% quit rate between treatment groups [11].
Allowing for a conservative attrition rate of 50%, the target number of
participants will be increased to a total of 276.
Baseline and demographic data will be listed for all treatment
groups. Summary statistics will be provided for each treatment group.
Safety data will be subjected to clinical review and summarized by
frequencies of events and mean changes from baseline.
The statistical analyses will include all subjects who took at least
one dose of randomized study medication. Subjects who discontinue the
study will be assumed to be smokers for the remainder of the study. In
computing the CQR, those subjects will be included in the denominator
but not in the numerator. A logistic regression model will be fitted to
compare the CQR and will include treatment as independent variables. .
The proportion of participants from each study group who will be
lost to follow-up, who will be abstinent will be computed from the 24
weeks follow-up data. Subjects who will not attend follow-up visits will
be considered smokers. The student T-test will be used to compare
between mean values of continuous variables in either intervention
groups, while the Chi-square test will be used to compare difference
between categorical variables. Multivariate logistic regression will be
used to identify independent predictors associated with continuous
abstinence.
2.9. Discontinuation criteria
This clinical study will be stopped when required study numbers are
achieved. Recruitment at the centre may be stopped for reasons of
particularly low recruitment, protocol violation, inadequate data re-
cording. Premature termination of this clinical trial may occur because
of a regulatory authority decision, change in opinion of the IRB and
drug safety problems.









Vital signs (HR, BP, WEIGHT) X
eCO X
Antidiabetic drug use X
Counseling X
Saliva tests X
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recorded in the case report form. A discontinuation occurs when an
enrolled subject ceases participation in the study, regardless of the
circumstances, prior to completion of the protocol. The investigator
must determine the primary reason for discontinuation. Withdrawal
due to adverse event should be distinguished from withdrawal due to
insufficient response. A discontinuation must be reported immediately
to the clinical monitor or his/her designated representative if it is due
to a serious adverse event. The final evaluation required by the protocol
will be performed at the time of study discontinuation. The investigator
will record the reason for study discontinuation, provide or arrange for
appropriate follow-up (if required) for such subjects, and document the
course of the subject's condition. Subjects who discontinue treatment
may continue participation in the study. Subjects will be required to
maintain the visit schedule and may be eligible to continue participa-
tion in the nontreatment phase of the study.
2.10. Ethics
University of Catania Institutional Review Board approved all re-
search procedures and we will obtain written informed consent form all
participants. This study must be conducted in compliance with
Institutional Review Board/Independent Ethics Committee (IRB/IEC)
and informed consent regulations. In addition, all local regulatory re-
quirements will be adhered to, in particular those which afford greater
protection to the safety of the trial participants. This study will be
conducted in general according to the Declaration of Helsinki and with
local laws and regulations relevant to the use of new therapeutic agents
in the country of conduct. The investigator, or a person designated by
the investigator, will explain the benefits and risks of participation in
the study to each subject, subject's legally acceptable representative or
impartial witness and obtain written informed consent prior to the
subject entering the study (before initiation of protocol-specified pro-
cedures). The informed consent document must be agreed to by IRB/
IEC and must be in compliance with ICH GCP and in accordance with
local regulatory and legal requirements, in language readily understood
by the subject. Each subject's original consent form, signed and dated by
the subject or by the subject's legally acceptable representative, and a
witness to the informed consent discussion, will be retained by the in-
vestigator.
2.11. Trial status
Recruitment of participants will start in June 2019 and enrolment is
expected to be completed in December 2019. Results will be reported in
2020.
3. Discussion
Recent studies of e-cigarettes for smoking cessation concluded that
nicotine e-cigarette help smokers quit long term [12–14]. The main
objective of the present study is to evaluate the efficacy of the use of
varenicline in smokers who use electronic cigarettes (single or dual
users) willing to quit. The transition from traditional cigarette to elec-
tronic cigarette can represent a first step towards the definitive exit
from cigarette addiction and the further passage could be represented
by the need to stop using also the electronic cigarette. Through the
implementation of this study it will be possible to observe changes at
the biological, psychological and behavioural level, on subjects that
benefit from the use of the varenicline plus counselling treatment.
We have described a randomized-controlled trial with a study
sample, composed of 140 subjects that exclusively smoke electronic
cigarette (single users) and 140 subjects that instead use both electronic
cigarette and classic cigarette (dual users), that will be divided into two
arms in order to evaluate the effects that the association between var-
enicline and counselling or placebo and counselling have on the
smoking/vaping behaviour. The varenicline and its use in terms of ef-
ficacy has been evaluated in several clinical studies that underlie the
observation of changes in the smoking behaviour of classical cigarette
smokers (≥10 cigarettes a day) [5–7]. The analysis of the results of
these studies have shown that abstinence from smoking has been de-
termined by the use of this molecule and has been evidenced by the
patient's self-test through a measurement of exhaled carbon monoxide
(CO≤10 ppm) at onsite visits [5–7]. There are currently no studies on
the use of varenicline to facilitate stop smoking nicotine electronic ci-
garettes in regularly exclusive e-cigarette users (single users) but there
is a recent study that enrolled 124 dual users interested in varenicline
use to help them in order to obtain a complete smoking cessation [8].
Of these 124 participants, 80 used varenicline and obtained the fol-
lowing abstinence rates at the 24-week follow-up, report: abstinence
from smoking 17.5%, vaping 12.5%, both smoking and vaping 8.8%.
There are challenges associated with a study of this nature. The
timing and nature of our study present unique challenges to recruit-
ment. We discussed this study with different e-cigarettes consumer as-
sociations and they acknowledge that e-cigarettes usage is the first
important time for smokers toward the smoking end game and they
enthusiastically supported the idea of providing help for trial recruit-
ment. Our primary aim on efficacy, rather than safety, is in direct re-
sponse to the presence of several specific studies about varenicline
delivered for 12 weeks. Intervention adherence is another challenge in
this study, as the ability to adapt to each participant's individual si-
tuation, needs, and personality traits are critical to developing ther-
apeutic alliance and engaging in a smoking cessation oriented inter-
vention. To address this, we will follow the published recommendations
established by the smoking cessation counselling derived by Standard
Treatment Programme [15].
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